Outcome for sinonasal malignancies: a population-based survey.
Adenocarcinoma
Head and neck cancer
Head and neck surgery
Mucosal melanoma
Multimodal cancer therapy
Sinonasal cancer
Journal
European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
ISSN: 1434-4726
Titre abrégé: Eur Arch Otorhinolaryngol
Pays: Germany
ID NLM: 9002937
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
15
06
2021
accepted:
23
08
2021
pubmed:
13
9
2021
medline:
9
4
2022
entrez:
12
9
2021
Statut:
ppublish
Résumé
Sinonasal malignancies (SNM) represent a rare and complex group of cancers that includes a wide range of histopathological subtypes. Data from population-based cohorts are scarce but warranted as a basis for randomized controlled treatment trials (RCTs). Our aim was to assess overall and histology subset-specific outcomes for SNM patients treated at a tertiary referral centre. A retrospective, population-based, consecutive cohort of patients with SNMs diagnosed from 2001 through 2019 was examined. Outcome was analysed in relation to age, gender, site, stage, histopathology, and treatment. Two-hundred and twenty-six patients were identified, whereof 61% presented with stage IV disease. 80% completed treatment with curative intent, which comprised surgery with neoadjuvant (29%) or adjuvant (37%) radiotherapy, monotherapy with surgery (22%), definitive chemoradiotherapy (7%), or radiotherapy (5%). Median follow-up was 106 months. The 5- and 10-year overall survival rates were 57% and 35%, respectively. Median overall survival was 76 months (esthesioneuroblastoma: 147 months; adenocarcinoma: 117; salivary carcinoma: 88; mucosal melanoma: 69; squamous cell carcinoma: 51, undifferentiated carcinoma: 42; neuroendocrine carcinoma: 9; and NUT-carcinoma 5). The 5- and 10-year disease-free survival rates were 63% and 54%, respectively, and disease-specific survival 83% and 66%. Increasing age, stage IVB, melanoma histopathology, and treatment with definitive chemoradiotherapy emerged as significant independent prognostic risk factors for disease-specific mortality (p ≤ 0.001). The results indicate a seemingly good outcome in comparison to previous reports, particularly for mucosal melanoma, adenocarcinoma, and undifferentiated carcinoma. The study provides additional background for future RCTs focusing on histology subset-specific treatment for SNM.
Identifiants
pubmed: 34510258
doi: 10.1007/s00405-021-07057-0
pii: 10.1007/s00405-021-07057-0
pmc: PMC8986678
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2611-2622Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2021. The Author(s).
Références
Stelow EB, Bishop JA (2017) Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: tumors of the Nasal Cavity, Paranasal Sinuses and Skull Base. Head Neck Pathol 11(1):3–15. https://doi.org/10.1007/s12105-017-0791-4 (PubMed PMID: 28247233; PubMed Central PMCID: PMCPMC5340732)
doi: 10.1007/s12105-017-0791-4
pubmed: 28247233
pmcid: 5340732
Robin TP, Jones BL, Gordon OM, Phan A, Abbott D, McDermott JD et al (2017) A comprehensive comparative analysis of treatment modalities for sinonasal malignancies. Cancer 123(16):3040–3049. https://doi.org/10.1002/cncr.30686 (PubMed PMID:28369832;PubMedCentralPMCID:PMCPMC6234843)
doi: 10.1002/cncr.30686
pubmed: 28369832
Van Dijk BA, Gatta G, Capocaccia R, Pierannunzio D, Strojan P, Licitra L et al (2012) Rare cancers of the head and neck area in Europe. Eur J Cancer 48(6):783–796. https://doi.org/10.1016/j.ejca.2011.08.021 (PubMed PMID: 22051735)
doi: 10.1016/j.ejca.2011.08.021
pubmed: 22051735
Thorup C, Sebbesen L, Dano H, Leetmaa M, Andersen M, Buchwald C et al (2010) Carcinoma of the nasal cavity and paranasal sinuses in Denmark 1995–2004. Acta Oncol 49(3):389–394. https://doi.org/10.3109/02841860903428176 (PubMed PMID: 20001493)
doi: 10.3109/02841860903428176
pubmed: 20001493
Koivunen P, Makitie AA, Back L, Pukkila M, Laranne J, Kinnunen I et al (2012) A national series of 244 sinonasal cancers in Finland in 1990–2004. Eur Arch Otorhinolaryngol 269(2):615–621. https://doi.org/10.1007/s00405-011-1615-x (PubMed PMID: 21590483)
doi: 10.1007/s00405-011-1615-x
pubmed: 21590483
Filtenborg MV, Lilja-Fischer JK, Sharma MB, Primdahl H, Kjems J, Plaschke CC et al (2021) Sinonasal cancer in Denmark 2008–2015: a population-based phase-4 cohort study from DAHANCA. Acta Oncol 60(3):333–342. https://doi.org/10.1080/0284186X.2021.1874618 (PubMed PMID: 33544640)
doi: 10.1080/0284186X.2021.1874618
pubmed: 33544640
Gore MR (2018) Survival in sinonasal and middle ear malignancies: a population-based study using the SEER 1973–2015 database. BMC Ear Nose Throat Disord 18:13. https://doi.org/10.1186/s12901-018-0061-4 (PubMed PMID:30116158;PubMedCentralPMCID:PMCPMC6085622)
doi: 10.1186/s12901-018-0061-4
pubmed: 30116158
pmcid: 6085622
Dulguerov P, Jacobsen MS, Allal AS, Lehmann W, Calcaterra T (2001) Nasal and paranasal sinus carcinoma: are we making progress? A series of 220 patients and a systematic review. Cancer 92(12):3012–3029. https://doi.org/10.1002/1097-0142(20011215)92:12%3c3012::aid-cncr10131%3e3.0.co;2-e (PubMed PMID: 11753979)
doi: 10.1002/1097-0142(20011215)92:12<3012::aid-cncr10131>3.0.co;2-e
pubmed: 11753979
Hafstrom A, Brun E, Persson S, Sjovall J, Wahlberg P, Greiff L (2019) Survival benefits from concomitant chemoradiotherapy before radical surgery in stage IVA sinonasal mucosal melanoma? Laryngoscope Investig Otolaryngol 4(6):624–631. https://doi.org/10.1002/lio2.317 (PubMedPMID:31890880;PubMedCentralPMCID:PMCPMC6929603)
doi: 10.1002/lio2.317
pubmed: 31890880
pmcid: 6929603
Koivunen P, Back L, Pukkila M, Laranne J, Kinnunen I, Grenman R et al (2012) Accuracy of the current TNM classification in predicting survival in patients with sinonasal mucosal melanoma. Laryngoscope 122(8):1734–1738. https://doi.org/10.1002/lary.23343 (PubMed PMID: 22549303)
doi: 10.1002/lary.23343
pubmed: 22549303
Lund VJ, Chisholm EJ, Howard DJ, Wei WI (2012) Sinonasal malignant melanoma: an analysis of 115 cases assessing outcomes of surgery, postoperative radiotherapy and endoscopic resection. Rhinology 50(2):203–210. https://doi.org/10.4193/Rhino11.267 (PubMed PMID: 22616083)
doi: 10.4193/Rhino11.267
pubmed: 22616083
Gilain L, Houette A, Montalban A, Mom T, Saroul N (2014) Mucosal melanoma of the nasal cavity and paranasal sinuses. Eur Ann Otorhinolaryngol Head Neck Dis 131(6):365–369. https://doi.org/10.1016/j.anorl.2013.11.004 (PubMed PMID: 24906226)
doi: 10.1016/j.anorl.2013.11.004
pubmed: 24906226
Lombardi D, Bottazzoli M, Turri-Zanoni M, Raffetti E, Villaret AB, Morassi ML et al (2016) Sinonasal mucosal melanoma: a 12-year experience of 58 cases. Head Neck 38(Suppl 1):E1737–E1745. https://doi.org/10.1002/hed.24309 (PubMed PMID: 26676523)
doi: 10.1002/hed.24309
pubmed: 26676523
Amit M, Tam S, Abdelmeguid AS, Kupferman ME, Su SY, Raza SM et al (2018) Patterns of treatment failure in patients with sinonasal mucosal melanoma. Ann Surg Oncol 25(6):1723–1729. https://doi.org/10.1245/s10434-018-6465-y (PubMed PMID: 29626308)
doi: 10.1245/s10434-018-6465-y
pubmed: 29626308
Hu R, Yang BB (2018) Surgery alone versus post-operative radiotherapy for sinonasal malignant melanoma: a meta-analysis. J Laryngol Otol 132(12):1051–1060. https://doi.org/10.1017/S0022215118002189 (PubMed PMID: 30674363)
doi: 10.1017/S0022215118002189
pubmed: 30674363
Grant-Freemantle MC, Lane O’Neill B, Clover AJP (2021) The effectiveness of radiotherapy in the treatment of head and neck mucosal melanoma: systematic review and meta-analysis. Head Neck 43(1):323–333. https://doi.org/10.1002/hed.26470 (PubMed PMID: 32926490)
doi: 10.1002/hed.26470
pubmed: 32926490
Jarrom D, Paleri V, Kerawala C, Roques T, Bhide S, Newman L et al (2017) Mucosal melanoma of the upper airways tract mucosal melanoma: a systematic review with meta-analyses of treatment. Head Neck 39(4):819–825. https://doi.org/10.1002/hed.24652 (PubMed PMID: 27898196)
doi: 10.1002/hed.24652
pubmed: 27898196
Abdelmeguid AS, Bell D, Hanna EY (2019) Sinonasal undifferentiated carcinoma. Curr Oncol Rep 21(3):26. https://doi.org/10.1007/s11912-019-0776-4 (PubMed PMID: 30806835)
doi: 10.1007/s11912-019-0776-4
pubmed: 30806835
Amit M, Abdelmeguid AS, Watcherporn T, Takahashi H, Tam S, Bell D et al (2019) Induction Chemotherapy Response as a Guide for Treatment Optimization in Sinonasal Undifferentiated Carcinoma. J Clin Oncol 37(6):504–512. https://doi.org/10.1200/JCO.18.00353 (PubMed PMID:30615549;PubMedCentralPMCID:PMCPMC6380524)
doi: 10.1200/JCO.18.00353
pubmed: 30615549
pmcid: 6380524
Lehrich BM, Goshtasbi K, Abiri A, Yasaka T, Sahyouni R, Papagiannopoulos P et al (2020) Impact of induction chemotherapy and socioeconomics on sinonasal undifferentiated carcinoma survival. Int Forum Allergy Rhinol 10(5):679–688. https://doi.org/10.1002/alr.22536 (PubMed PMID: 32104985)
doi: 10.1002/alr.22536
pubmed: 32104985
Nilsson JS, Sobti A, Swoboda S, Erjefalt JS, Forslund O, Lindstedt M et al (2020) Immune Phenotypes of Nasopharyngeal Cancer. Cancers 12(11):3428. https://doi.org/10.3390/cancers12113428 (PubMed PMID: 33218184; PubMed Central PMCID: PMCPMC7699205)
doi: 10.3390/cancers12113428
pmcid: 7699205
Konig M, Osnes T, Bratland A, Jebsen P, Meling TR (2020) Treatment of Sinonasal Adenocarcinoma: A Population-Based Prospective Cohort Study. J Neurol Surg B Skull Base 81(6):627–637. https://doi.org/10.1055/s-0039-1694050 (PubMed PMID:33381366;PubMedCentralPMCID:PMCPMC7755507)
doi: 10.1055/s-0039-1694050
pubmed: 33381366
Joshi RR, Husain Q, Roman BR, Cracchiolo J, Yu Y, Tsai J et al (2019) Comparing Kadish, TNM, and the modified Dulguerov staging systems for esthesioneuroblastoma. J Surg Oncol 119(1):130–142. https://doi.org/10.1002/jso.25293 (PubMed PMID:30466166;PubMedCentralPMCID:PMCPMC6352736)
doi: 10.1002/jso.25293
pubmed: 30466166
Kadish S, Goodman M, Wang CC (1976) Olfactory neuroblastoma. A clinical analysis of 17 cases. Cancer 37(3):1571–1576. https://doi.org/10.1002/1097-0142(197603)37:3<1571::aid-cncr2820370347>3.0.co;2-l PubMed PMID: 1260676
Dulguerov P, Calcaterra T (1992) Esthesioneuroblastoma: the UCLA experience 1970–1990. Laryngoscope 102(8):843–849. https://doi.org/10.1288/00005537-199208000-00001 (PubMed PMID: 1495347)
doi: 10.1288/00005537-199208000-00001
pubmed: 1495347
Jethanamest D, Morris LG, Sikora AG, Kutler DI (2007) Esthesioneuroblastoma: a population-based analysis of survival and prognostic factors. Arch Otolaryngol Head Neck Surg 133(3):276–280. https://doi.org/10.1001/archotol.133.3.276 (PubMed PMID: 17372086)
doi: 10.1001/archotol.133.3.276
pubmed: 17372086